{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:19:38Z","timestamp":1785154778844,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["680"],"award-info":[{"award-number":["680"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.biopha.2021.112091","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T17:29:40Z","timestamp":1630344580000},"page":"112091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan"],"prefix":"10.1016","volume":"143","author":[{"given":"Elham","family":"Fakhr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Azadmanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Teimoori-Toolabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.biopha.2021.112091_bib1","first-page":"345","article-title":"Sixty years of CA: a cancer journal for clinicians","volume":"60","author":"Gansler","year":"2010","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.biopha.2021.112091_bib2","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.biopha.2021.112091_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3325\/cmj.2011.52.478","article-title":"Cancer epidemiology in Central and South Eastern European countries","volume":"52","author":"Vrdoljak","year":"2011","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.biopha.2021.112091_bib4","doi-asserted-by":"crossref","first-page":"S312","DOI":"10.1016\/S0959-8049(11)70183-6","article-title":"Current standards and new trends in the primary treatment of colorectal cancer","volume":"47","author":"Stein","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"9317","key":"10.1016\/j.biopha.2021.112091_bib5","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0140-6736(02)08514-8","article-title":"Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial","volume":"359","author":"Maughan","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2021.112091_bib6","unstructured":"R. Gorlick, J.R. Bertino, editors. Drug resistance in colon cancer. Seminars in oncology, 1999."},{"key":"10.1016\/j.biopha.2021.112091_bib7","unstructured":"E. Raymond, S. Faivre, J.M. Woynarowski, S.G. Chaney, editors. Oxaliplatin: mechanism of action and antineoplastic activity. Seminars in oncology, 1998."},{"issue":"5","key":"10.1016\/j.biopha.2021.112091_bib8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2021.112091_bib9","first-page":"202","article-title":"In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction","volume":"7","author":"Kanzawa","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2021.112091_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0306-3623(98)00191-8","article-title":"Resistance to 5-fluorouracil","volume":"31","author":"Mader","year":"1998","journal-title":"Gen. Pharmacol. Vasc. Syst."},{"issue":"12","key":"10.1016\/j.biopha.2021.112091_bib11","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/annonc\/mdf337","article-title":"Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity","volume":"13","author":"Xu","year":"2002","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2021.112091_bib12","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1158\/1535-7163.MCT-14-0636","article-title":"Tumor-related molecular mechanisms of oxaliplatin resistance","volume":"14","author":"Martinez-Balibrea","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2021.112091_bib13","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.biopha.2018.09.112","article-title":"Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p","volume":"108","author":"Ghanbarian","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2021.112091_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2021.112091_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.biopha.2021.112091_bib16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3892\/mmr_00000140","article-title":"Stable reversal of multidrug resistance in colon cancer cells by RNA interference targeting the MDR1 gene","volume":"2","author":"Xia","year":"2009","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2021.112091_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2016.03.001","article-title":"ABC transporters as mediators of drug resistance and contributors to cancer cell biology","volume":"26","author":"Fletcher","year":"2016","journal-title":"Drug Resist. Updates"},{"issue":"2","key":"10.1016\/j.biopha.2021.112091_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0092-8674(00)00122-7","article-title":"Linking colorectal cancer to Wnt signaling","volume":"103","author":"Bienz","year":"2000","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.biopha.2021.112091_bib19","first-page":"2041","article-title":"Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells","volume":"30","author":"Chikazawa","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2021.112091_bib20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1146\/annurev.cellbio.20.010403.113126","article-title":"The Wnt signaling pathway in development and disease","volume":"20","author":"Logan","year":"2004","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2021.112091_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.12688\/f1000research.7579.1","article-title":"Wnt signaling in cancer stem cells and colon cancer metastasis","volume":"5","author":"Basu","year":"2016","journal-title":"F1000Research"},{"issue":"7035","key":"10.1016\/j.biopha.2021.112091_bib22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nature03319","article-title":"Wnt signalling in stem cells and cancer","volume":"434","author":"Reya","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2021.112091_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.gendis.2016.01.002","article-title":"Transition to resistance: an unexpected role of the EMT in cancer chemoresistance","volume":"3","author":"Wang","year":"2016","journal-title":"Genes Dis."},{"key":"10.1016\/j.biopha.2021.112091_bib24","doi-asserted-by":"crossref","first-page":"8904","DOI":"10.1038\/ncomms9904","article-title":"Wnt\/\u03b2-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance","volume":"6","author":"Wickstr\u00f6m","year":"2015","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.biopha.2021.112091_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12341","article-title":"miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1\/P-gp expression","volume":"50","author":"Zhou","year":"2017","journal-title":"Cell Prolif."},{"issue":"1","key":"10.1016\/j.biopha.2021.112091_bib26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1074\/jbc.M114.590364","article-title":"Inhibition of transient receptor potential channel 5 reverses 5-Fluorouracil resistance in human colorectal cancer cells","volume":"290","author":"Wang","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2021.112091_bib27","first-page":"2041","article-title":"Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells","volume":"30","author":"Chikazawa","year":"2010","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.biopha.2021.112091_bib28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1006\/cbir.2002.0901","article-title":"Direct evidence for a role of \u03b2\u2010catenin\/lef\u20101 signaling pathway in induction of EMT","volume":"26","author":"Kim","year":"2002","journal-title":"Cell Biol. Int."},{"issue":"5","key":"10.1016\/j.biopha.2021.112091_bib29","first-page":"895","article-title":"Suppression of intestinal polyposis in Mdr1-deficient ApcMin\/+ mice","volume":"63","author":"Yamada","year":"2003","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.biopha.2021.112091_bib30","first-page":"4761","article-title":"Transactivation of the multidrug resistance 1 gene by T-cell factor 4\/\u03b2-catenin complex in early colorectal carcinogenesis","volume":"60","author":"Yamada","year":"2000","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2021.112091_bib31","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/CAD.0000000000000118","article-title":"TCF4 silencing sensitizes the colon cancer cell line to oxaliplatin as a common chemotherapeutic drug","volume":"25","author":"Gheidari","year":"2014","journal-title":"Anti-Cancer Drugs"},{"issue":"4","key":"10.1016\/j.biopha.2021.112091_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/cgt.2016.4","article-title":"Precise and efficient siRNA design: a key point in competent gene silencing","volume":"23","author":"Fakhr","year":"2016","journal-title":"Cancer Gene Ther."},{"issue":"11","key":"10.1016\/j.biopha.2021.112091_bib33","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1080\/15384047.2016.1235657","article-title":"MiR-339 and especially miR-766 reactivate the expression of tumor suppressor genes in colorectal cancer cell lines through DNA methyltransferase 3B gene inhibition","volume":"17","author":"Afgar","year":"2016","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2021.112091_bib34","first-page":"105","article-title":"Selective suicide gene therapy of colon cancer cell lines exploiting fibroblast growth factor 18 promoter","volume":"25","author":"Teimoori-Toolabi","year":"2010","journal-title":"Cancer Biother. Radiopharm."},{"issue":"2","key":"10.1016\/j.biopha.2021.112091_bib35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CAD.0000000000000175","article-title":"Silencing the wild-type and mutant K-ras increases the resistance to 5-flurouracil in HCT-116 as a colorectal cancer cell line","volume":"26","author":"Teimoori-Toolabi","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.biopha.2021.112091_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1471-230X-12-53","article-title":"The balance between two isoforms of LEF1 regulates colon carcinoma growth","volume":"12","author":"Wang","year":"2012","journal-title":"BMC Gastroenterol."},{"issue":"19","key":"10.1016\/j.biopha.2021.112091_bib37","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1093\/nar\/gkq492","article-title":"A role for YY1 in repression of dominant negative LEF1 expression in colon cancer","volume":"38","author":"Yokoyama","year":"2010","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.biopha.2021.112091_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108253","article-title":"Optimizations of siRNA design for the activation of gene transcription by targeting the TATA-box motif","volume":"9","author":"Fan","year":"2014","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.biopha.2021.112091_bib39","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1128\/MCB.00105-06","article-title":"Wnt activation and alternative promoter repression of LEF1 in colon cancer","volume":"26","author":"Li","year":"2006","journal-title":"Mol. Cell. Biol."},{"issue":"6929","key":"10.1016\/j.biopha.2021.112091_bib40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature01458","article-title":"Links between signal transduction, transcription and adhesion in epithelial bud development","volume":"422","author":"Jamora","year":"2003","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.biopha.2021.112091_bib41","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1073\/pnas.96.10.5522","article-title":"The cyclin D1 gene is a target of the \u03b2-catenin\/LEF1 pathway","volume":"96","author":"Shtutman","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.biopha.2021.112091_bib42","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.bcp.2007.01.037","article-title":"Inhibition of G1\/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines","volume":"73","author":"Rakitina","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2021.112091_bib43","first-page":"2531","article-title":"Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells","volume":"30","author":"Seetharam","year":"2010","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2021.112091_bib44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10585-012-9552-7","article-title":"Nuclear LEF1\/TCF4 correlate with poor prognosis but not with nuclear \u03b2-catenin in cerebral metastasis of lung adenocarcinomas","volume":"30","author":"Bleckmann","year":"2013","journal-title":"Clin. Exp. Metastas."},{"issue":"1","key":"10.1016\/j.biopha.2021.112091_bib45","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4161\/cbt.11.1.13672","article-title":"Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death","volume":"11","author":"Ametller","year":"2011","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2021.112091_bib46","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/kisup.2014.16","article-title":"Wnt\/\u03b2-catenin signaling and kidney fibrosis","volume":"4","author":"Tan","year":"2014","journal-title":"Kidney Int. Suppl."},{"issue":"8","key":"10.1016\/j.biopha.2021.112091_bib47","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4161\/cbt.7.8.6302","article-title":"Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: the roles of caspase-6 and p53","volume":"7","author":"Chan","year":"2008","journal-title":"Cancer Biol. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2021.112091_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0128-8","article-title":"Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells","volume":"50","author":"He","year":"2018","journal-title":"Exp. Mol. Med."},{"issue":"12","key":"10.1016\/j.biopha.2021.112091_bib49","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/carcin\/bgr222","article-title":"Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy","volume":"32","author":"Kendziorra","year":"2011","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.biopha.2021.112091_bib50","first-page":"1667","article-title":"Radiosensitization by irinotecan is attributed to G2\/M phase arrest, followed by enhanced apoptosis, probably through the ATM\/Chk\/Cdc25C\/Cdc2 pathway in p53-mutant colorectal cancer cells","volume":"53","author":"Wang","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2021.112091_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/476974","article-title":"Regulations of P-Glycoprotein\/ABCB1\/MDR1 in human cancer cells","volume":"2014","author":"Katayama","year":"2014","journal-title":"N. J. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2021.112091_bib52","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/cas.12223","article-title":"Inhibition of Wnt\/\u03b2\u2010catenin signaling downregulates P\u2010glycoprotein and reverses multi\u2010drug resistance of cholangiocarcinoma","volume":"104","author":"Shen","year":"2013","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2021.112091_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/molecules25112576","article-title":"Quercetin inhibits lef1 and resensitizes docetaxel-resistant breast cancer cells","volume":"25","author":"Prieto-Vila","year":"2020","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.biopha.2021.112091_bib54","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ijc.20032","article-title":"ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases","volume":"109","author":"Candeil","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2021.112091_bib55","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.leukres.2004.03.013","article-title":"Caveolin-1 and cancer multidrug resistance: coordinate regulation of pro-survival proteins?","volume":"28","author":"Shatz","year":"2004","journal-title":"Leuk. Res"},{"issue":"10","key":"10.1016\/j.biopha.2021.112091_bib56","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3748\/wjg.v23.i10.1816","article-title":"miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-beta\/Smad4 pathway","volume":"23","author":"Sun","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"16","key":"10.1016\/j.biopha.2021.112091_bib57","doi-asserted-by":"crossref","first-page":"22077","DOI":"10.18632\/oncotarget.7895","article-title":"The TGF-beta pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells","volume":"7","author":"Romano","year":"2016","journal-title":"Oncotarget"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222100874X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222100874X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:44:02Z","timestamp":1771919042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222100874X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":57,"alternative-id":["S075333222100874X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112091","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112091"}}